# VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial

> **NCT03820947** · NA · TERMINATED · sponsor: **Medtronic Endovascular** · enrollment: 506 (actual)

## Conditions studied

- Venous Reflux

## Interventions

- **DEVICE:** VenaSeal™ System
- **DEVICE:** Endothermal Ablation (ETA)
- **PROCEDURE:** Surgical Stripping

## Key facts

- **NCT ID:** NCT03820947
- **Lead sponsor:** Medtronic Endovascular
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-05
- **Primary completion:** 2024-06-12
- **Final completion:** 2025-11-10
- **Target enrollment:** 506 (ACTUAL)
- **Why stopped:** Follow-up of the VenaSeal vs. Endothermal Ablation and Venous Leg Ulcer studies was concluded early due to increased evidence of safety and effectiveness of VenaSeal in published literature and to reduce burden to investigators and sites.
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03820947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03820947, "VenaSeal Spectrum: Global Post-Market Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03820947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*